Milrinone Zentiva (Milrinone)

Milrinone is an inotropic agent used in the management of severe cardiac conditions where low cardiac output is a concern.

• Acute decompensated heart failure: enhances myocardial contractility to improve systemic perfusion.
• Cardiogenic shock: provides rapid hemodynamic support to sustain blood pressure and organ perfusion.
• Low cardiac output state (post‑operative or after myocardial infarction): helps maintain adequate circulation while other therapies are optimized.

• Milrinone inhibits phosphodiesterase‑3 enzymes, leading to an accumulation of intracellular cyclic adenosine monophosphate (cAMP) in cardiac myocytes and vascular smooth‑muscle cells. Elevated cAMP enhances calcium influx during systole, producing a positive inotropic effect, while simultaneously causing vasodilation of peripheral vessels, which reduces afterload and improves overall cardiac output.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hypotension: reduction in systemic blood pressure.
• Tachyarrhythmias: increased heart rate or irregular rhythm.
• Headache: mild to moderate discomfort.
• Nausea: gastrointestinal upset.
• Flushing: warmth and redness of the skin.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Severe hypotension: potentially leading to shock.
• Ventricular arrhythmias: life‑threatening heart rhythm disturbances.
• Myocardial ischemia: reduced blood flow to heart muscle.
• Thrombocytopenia: low platelet count increasing bleeding risk.
• Anaphylactic reactions: severe allergic response.
• Cardiac arrest: sudden loss of heart function.

Milrinone requires careful monitoring and specific precautions to ensure patient safety.

• Blood pressure monitoring: watch for hypotension and adjust infusion rate as needed.
• Cardiac rhythm surveillance: continuous ECG to detect arrhythmias.
• Renal function assessment: dose may need adjustment in renal impairment.
• Recent myocardial infarction: use cautiously due to risk of ischemia.
• Concomitant vasodilators: avoid excessive blood pressure drops.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

• Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.
• Concurrent high‑dose vasodilators: risk of profound hypotension.
• Multiple inotropes: heightened arrhythmia potential.
• Class IA anti‑arrhythmics: increased pro‑arrhythmic risk.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic response.
• Diuretics: monitor electrolyte balance and volume status.
• ACE inhibitors or ARBs: watch for additive blood pressure effects.
• Calcium channel blockers: potential for altered vascular tone.
• Anticoagulants: monitor for bleeding if thrombocytopenia occurs.